Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Obese Subjects with a History of Type 2 Diabetes Mellitus

Next Previous
X
Search
Trial Profile

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Obese Subjects with a History of Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cotadutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors MedImmune

    • Most Recent Events

    • 13 Nov 2018 Results assessing the relationship between the effects of MEDI0382 on hepatic fat reduction (n=51) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 05 Oct 2018 Results (n=51) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 05 Oct 2018 Results (n=61) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top